China Regulator Tightens Guideline On Biological Products, Including Vaccines
China Regulator Tightens Guideline On Biological Products, Including Vaccines
China's market regulator said on Monday it had tightened up a guideline for inspection of biological products, including vaccines, before a batch is sold or imported.

BEIJING: China’s market regulator said on Monday it had tightened up a guideline for inspection of biological products, including vaccines, before a batch is sold or imported.

The new guideline, effective from March 1 next year, adds a requirement that provincial-level medical product regulators are responsible for investigating major flaws that could impact product quality in companies’ manufacturing process in their region, State Administration For Market Regulation said on its website.

The new guideline also specifies situations where inspection of pre-sale or pre-imported batches of such products could be waived, SAMR said.

China has allowed vaccines, if they are used to cope with infectious disease epidemics or other emergencies, to be exempted from inspection procedures, known as lot release, after approval from State Council’s medical product regulating department.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Read all the Latest News, Breaking News and Coronavirus News here

What's your reaction?

Comments

https://shivann.com/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!